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Abstract: The title compound was prepared by an improved variant of the literature procedure, and metal
complexes containing its anion and the following metal ions: Zn(II), Cd(II), Hg(II), Co(II), Ni(II), Cu(II),
V(IV), Fe(III) and Ag(I) were synthesized and characterized by standard procedures (elemental analysis; IR,
electronic, NMR and EPR spectroscopy; TG, magnetic and conductimetric measurements). The parent
sulfonamide and its metal complexes are potent inhibitors of two carbonic anhydrase (CA) isozymes, CA I
and II, and they might possess applications as selective cerebrovasodilating agents.
Introduction
Heterocyclic sulfonamides possessing carbonic anhydras (CA, EC 4.2.1.1) inhibitory properties are
clinically used pharmacological agents in the treatment of a variety of diseases.2 Thus, acetazolamid 1 and
some other thiadiazole-sulfonamides derived from 2, methazolamid 3, thoxzolamide 4 and sezolamid 5
represent several generation of such drugs, used in the last 40 years in the treatment or prevention of
2a c d 2b glaucoma, gastro-duodenal ulcers, mountain sickness3 and other conditions associated with acid-base
disequilibria.2a
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As it was observed that sulfonamides possessing a bicyclic ring system such as 4 or 5 are generally
stronger inhibitors for several of the eight CA isozymes presently known in vertebrates,4 as compared to
derivatives containing only one such homo- or heterocyclic ring system,2a,5 much synthetic work has been
devoted to the preparation and evaluation of such compounds, in order to obtain stronger and more selective
inhibitors, for diverse medical applications.6-8
Sa 6a Compounds such as 6 and 7, 8 not only showed excellent inhibitory properties against the
major red ceil isozyme, CA II,2,3 but also possessed interesting pharmacological qualities, making them
candidates for the development of topical antiglaucoma agents in the cas of 6,,8 and selctiv
cerebrovasodilators, in the case of 7.6 As no selective such pharmacological agents are known up to now, the
development of a selective cerebrovasodilator would constitute a good approach for th treatment of
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cerebrovascular disease, a condition becoming more stringent in the last period, as the number of elderly
people is increasing.6
Recently, it was also reported9,1 that metal complexes of heterocyclic sulfonamides such as 1-5
behave as even stronger CA inhibitors as compared to the ligands from which they derive. Thus, a large
number of such derivatives were prepared and assayed as inhibitors of three CA isozymes up to now, i.e.,
CA I, II and IV, in the search for isozyme-specific inhibitors. Continuing our research for specific inhibitors,
in this paper we report the preparation of metal complexes of sulfonamide 8 possessing very good CA
inhibitory properties. The Zn(II), Cd(II), Hg(II), Co(II), Ni(II), Cu(II), V(IV), F(III) and AgO) complexes
containing the conjugate base of this sulfonamide were obtained and characterized by standard procedures
(elemental analysis, IR, electronic, NMR and EPR spectroscopy; TG, magnetic and conductimetric
measurements).
Materials and Methods
IR spectra ofKBr pellets were recorded on a Perkin-Elmer 16PC FTIR instrument, in the range 200-
4000 cm". Solution electronic spectra were recorded with a Cary 3 spectrophotometer interfaced with a PC.
Electronic spectra were obtained by the diffuse reflectance technique in MgO as reference, with a Perkin
Elmer Lambda 15 apparatus, in the range 200-900 cm"1. Conductimetric measurements were done in DMF
solutions, at 25C (concentrations of mM of complex) with a Fisher conductimeter. H-NMR spectra were
recorded with a Bruker CPX-200 instrument working at 200 MHz, in DMSO-d6 as solvent. Chemical shifts
are expressed as i values relative to Me4Si as external standard. EPR spectra were recorded on a Varian E-9
spectrometer at room temperature, in crystalline powder. The field was calibrated using crystalline
diphenylpicrylhydrazyl (g 2.0036). Magnetic susceptibility measurements were carried out at room
temperature with a fully automated AZTEC DSM8 pendulum-type susceptometer. Mercury(II)
tetrakis(thiocyanato)cobaltate(II) was used as a susceptibility standard. Corrections for the diamagnetism were
estimated from Pascal’s constants.1 Elemental analyses were done by combustion for C,H,N with an
automated Carlo Erba analyzer, and gravimetrically for the metal ions, and were 0.4% of the theoretical
values. Thermogravimetric measurements were done in air, at a heating rate of 10C/rain., with a Perkin
Elmer 3600 thermobalance.
Acetazolamide and methazolamide used in the enzymatic assay as standards and for the preparation
of2 and 8 were from Sigma. Sulfonamide 2 was prepared as described in the previous paper by deacetylation
of acetazolamide, whereas 8 was obtained by an improvement of the literature procedure6a by condensation
of 5-amino-l,3,4-thiadiazole-2-sulfonamide 2 with diethyl chloroacetal (see later in the text). Diethyl
chloroacetal was from Acros; metal salts and solvents were from Merck. Human CA I and CA II cDNAs
were expressed in Escherichia coli strain BL21 (DE3) from the plasmids pACA/HCA I and pACA/HCA II
(the two plasmids were a gift from Prof. Sven Lindskog, Umea University, Sweden). Cell growth conditions
were those described by Lindskog’s group,2 and enzymes were purified by affinity chromatography
according to the method of Khalifah et al.3 Enzyme concentrations were determined spectrophotometrically
at 280 rim, using a molar absorptivity of 49 mM-. cm"1 for CA I and 54 mM’l.cm" for CA II,
respectively, based on Mr= 28.85 kDa for CA I, and 29.3 kDa for CA II, respectively. 14
Initial rates of 4-nitrophenyl acetate hydrolysis were monitored spectrophotometrically, at 400 nm
and 25C, with a Cary 3 apparatus interfaced with an IBM compatible PC by the method of Pocket and
Stone.5. Solutions of substrate were prepared in anhydrous acetonitrile; the substrate concentrations varied
between 10.2 and 10-5 M. A molar absorption coefficient (e 18,400 M’.cm" was used for the 4-
nitrophenolate formed by hydrolysis, in the conditions of the experiments (pH 7.80), as reported by Pocker
and Stone. 15 Non-enzymatic hydrolysis rates were always subtracted from the observed rates. Duplicate
experiments were done for each inhibitor, and the values reported throughout the paper are the averages of
such results. ICs0 represents the molarity of inhibitor producing a 50% decrease of enzyme catalyzed
hydrolysis of 4-nitrophenyl acetate.
Synthesis of imidazo[2,l-b]-l,3,4-thiadiazole-2-sulfonamide 8
1.80 g (10 mmol) of 5-amino-l,3,4-thiadiazole-2-sulfonamide 2 and 1.4 mL (10 mmol) of triethylamine
were suspended in 50 mL of anhydrous acetonitrile, then 1.27 mL (11 mmol) of diethyl chloroacetal were
added and the mixture was magnetically stirred at room temperature for 5 hours and then heated at
refluxation for 24 hours. The title compound precipitated by cooling, was filtered and recrystallized from
ethanol (69 % yield ). Presumably, a Schiff base intermediate is formed during the first step, as reported for
related sulfonamide derivatives, 16 which subsequently cyclizes intramolecularly, in the presence of
triethylamine, with formation of the imidazo-thiadiazole ring system.6a The title compound was previously
reported as hydrobromide salt (m.p. 207-210C)6a being obtained with a 26 % yield, by a synthetic
procedure similar to the one described above, except for the lack of triethylarnine in the reaction medium.6a
As seen from our data, the use of the base leads to a highly improved synthesis yield. The title compound
o was obtained as a white powder, m.p. 255-258 C; IR (KBr),.cm" 633, 709, 752, 915, 1030, 1175, 1358,
1540, 1610, 3160; UV (MeOH): ’max 262 nm (lg e 2.75); H-NMR (DMSO-d6), i, ppm: 7.45-7.92 (m,
2H, CH=CH); 8.48 (br s, 2H, SO2NH). The last signal disappears after 5 rain by addition ofD20 into the
NMR tube. Analysis, found: C, 23.3; H, 2.0; N 27.0 %; C4H4N402S2 requires: C, 23.5; H, 1.9;N, 27.4%.
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General procedure for the preparation of metal complexes 9-17
.An amount of 0.102 g (0.5 retool) of sulfonamide 8 were suspended in 10 mL MeOH and the calculated
amount of aqueous N NaOH solution was added in order to obtain the sodium salt RSOaNHNa. This was
treated thereafter with an aqueous solution of the metal salt (AgNO; chlorides for Zn(II), Cd(II), Hg(II),
Cu(II), CoO0 and i(II); vanadyl sulfate, and Fe(III) perehlorate), wrking at molar ratios Mn+ RSO2NH"
of 1:1 (for the AgO) derivatives); 1:2 (for the divalent metal ions and V(IV)); and 1:3 (for the Fe(III)
derivative), respectively. The reaction mixture was heated on a steam bath for 3 hours, then the precipitated
complexes were filtered, thoroughly washed with cold water and alcohol. Crystallization was not done as the
only solvents in which the complexes have good solubility are DM$O and DMF. The complexes 9-17 melt
with decomposition at temperatures higher than 330 C.
Results and Discussion
Barnish et al.6a reported the synthesis and murine erythrocyte CA (a mixture of isozymes CA I and
CA II)2 inhibitory properties of a series of imidazo-l,3,4-thiadiazole-sulfonamides oftype 7, prepared in the
search of a selective cerebrovasodilating agent. As the parent compound of this homologous series, 8,
possesses an interesting donor system for obtaining metal complexes, we reinvestigated its synthesis and
properties. The general synthetic method for obtaining this ring system involves condensation of 5-amino-
1,3,4-thiadiazole-2-sulfonamide 2 with ((x-halogeno-ketones (or halogenoacetaldehyde or their functional
derivatives in the case of the parent compound 8). The synthetic procedures used by us is shown in Scheme
1.
N---N + ClCH2CH(OEt) 2
EtOH
Cl
2 lEt3
N
HCl
100"C
Scheme 1 N---N IL #L NS "SO2NH:
8
Thus, condensation of 2 with diethyl chloroacetal in acetonitrile, at room temperature initially, and
then at reflux, in the presence of triethylamine, led to imidazo[2,1-b]-l,3,4-thiadiazole-2-sulfonamide 8 with
a 69% yield. The highly increased yield in the presence of triethylamine prompted us to hypothesize that the
reaction proceeds in two steps, as shown in Scheme 1. In the first one, occurring at room temperature, a
Schiff base is probably formed, which was not isolated, as it reacted in the second step to form the desired
product. This type of reaction involving Schiff bases has in fact been thoroughly investigated by this
group 16 for the reaction of 2 as well as other amino-sulfonamides with a large series of aldehydes and
ketones. In the second step, taking place at higher temperatures, the Schiff base cyclizes intramolecularly
with formation of hydrochloric acid and the imidazo-thiadiazole ring system. The presence of triethylamine
presumably favors this step, and might explain the improved yield of our synthetic variant, as compared to
the original one of Barnish et al.6a The obtained compound was extensively characterized by physico-
chemical methods (see Materials and Methods) which confirmed the proposed structure (only melting point
and elemental analysis have been reported for 8 in ref.6a).
The metal complexes containing the conjugate base of sulfonamide 8 and transition metal ions are
shown in Table I, together with their elemental analysis data (0.4% ofthe theoretical values).
The newly prepared compounds, 9-17, have also been characterized by spectroscopic (IR, EPR,
electronic, and H-NMR), magnetic, conductimetric and thermogravimetric (TG) measurements. Some of
these data are shown in Tables II and III.
In the IR spectra of complexes 9-17, the following fe.amres were observed: (i) the shift of the two
sulfonamido vibrations to lower wavenumbers (with 5-15 cm" for the symmetric vibration, and 8-18 cm"1
for the antisymmetric one, respectively), as compared to the corresponding bands in the spectra of the
original sulfonamide 8; (ii) a similar shift of the C=N vibration (at 1610 cm" in 8), generally atributed to
the thiadiazolic moiety,9,1,16 which for the complexes appears at 1600 cm"l. The only exception is
constituted by the silver comPlleX 17, for which two broad bands are seen in this region, one at 1580 cm"1
and the other one at 1610 cm", but higly reduced in intensity as compared to the corresponding band of 8;
(iii) the absence ofy(NH) vibrations, which for 8 appeared at 3160 cm’l; (iv) the presence ofv(OH) bands,
at around 3400 cm" in the spectra ofcomplexes 14 and 15 containing coordinated water molecules (data not
shown). All these data suggest the participation of the deprotonated sulfonamido moiety and endocyclic
nitrogen(s) of the ligand in coordinating the metal ions in the prepared complexes.
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Table I: Prepared complexes 9-17, containing the conjugate base of sulfonamide 8 and their elemental
analysis data (L stands for the sulfonamide deprotonated species of $).
No. Complex Color Yield Analysis (calculated/fpund)
(%) %Ma %Cb %Ho %Nb
9 [ZnL2] white 81 13.8/13.5 20.3/20.1 1.2/1.0 23.7/23.4
10 [CdL2! white 87 21.7/21.3 18.5/18.6 1.1/0.8 21.6/21.5
11 [HgL2] white 93 33.0/33.2 15.8/15.7 0.9/0.9 18.4/18.0
12 [VOL ] gray 79 10.7/11.1 20.3/20.1 1.2/1.3 23.6/23.3
13 t 8 3/1.3 25.2/25.0 brown 94 1.6/21.5 [FeL .4/8.0 2
14 [CoL-2(OH2)2] pink 62 11.7/11.7 19.1/18.8 2.0/2.1 22.3/22.1
15 [NiL2OH2)2] green 84 11.7/11.8 19.1/19.2 1.9/1.6 22.3/21.9
16 [CuLo][
blue 73 13.5/13.7 20.4/20.2 1.2/0.9 23.8/23.6
17 [AgL n white 95 34.6/34.7 15.4/15.7 0.9/0.9 18.0/17.9
aBy gravimetry; bBy combustion.
Table II: Spectroscopic, thermogravimetric and conductimetric data for compounds 8-17.
Comp. IR Spectraa ,cm-1 Electronic Spectrab TG analysisc Conductimetryd
(SO2)S (SO2)as (C=N) Z,(nm) (lge) calc./found AM (ohm-1 x cm2x mol-1)
$ 1175; 1358 1610 262 (2.75) e 11
9 1170; 1346 1600 271 (3.05) e 7
10 1170; 1347 1600 278 (3.12) e 8
11 1170; 1345 1595 276 (3.09) e 10
12 1163; 1340 1600 270 (3.06) e 11
13 1165; 1-344 1600 272 (3.21) e 9
14 1170; 1345 1600 277 (3.08) 7.1/6.9f 11
15 1170; 1345 1600 277 (3.01) 7.1/7.1 f 10
16 1170; 1340 1600 275 (3.11) e 9
17 1160; 1350 1580; 1610 289 (4.09) e 6
a In KBr; bin DMSO; cWeight loss between 130-200 C; d 10-3 M solution, in DMF, at 25C; e No weight
loss seen under 250 C; f Corresponding to two coordinated water molecules, lost at 180-190 C.
Table III: Diffuse reflectance spectra, magnetic moments and proposed geometries for complexes 9-17.
Complex Electronic spectra (), cm-1)a geff (BM)b Geometry
9 c d tetrahedral
10 c d tetrahedral
11 c d tetrahedral
12 25,760; 15,400; 11,800(sh) 1.85 square pyramidal
13 24,600; 20,500; 10,500 5.74 octahedral
14 25,200; 20,700(sh); 15,300 4.90 octahedral
15 17,600; 11,500 3.40 octahedral
16 14,500 1.98 distorted tetrahedral
17 c d lineal
a In MgO as standard material; b At room temperature; c No transitions seen; a Diamagnetic.
Solution electronic spectra of the complexes and the sulfonamide 8 confirmed the above mentioned
10 16 assumption. Thus, the characteristic band of the conjugated thiadiazolo-sulfonamide system, appearing
at 262 nm in the spectrum of 8, undergoes bathochromic shifts (with 8-17 nm) and hyperchromic effects in
the sodium salt of 8 (data not shown) as well as the complexes 9-17, similarly to other metal complexes of
sulfonamides of type 1-5 previously reported by us.9,10
Conductimetry proved the non-electrolyte nature of 8 and of all complexes 9-17, whereas TG
analysis detected the presence oftwo coordination water molecules in the Co(II) and Ni(II) derivatives (Table
II). No decomposition steps under 250C were evidenced for the other metal complexes, whereas at higher
temperatures intricate decomposition patterns were observed, with oxidation of the organic moieties of the
complexes (data not shown).
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Diffuse reflectance electronic spectra and magnetic susceptibility data at room temperature of the
complexes containing paramagnetic metal ions (Table III) indicated the geometry of the central metal ions,
which are square pyramidal for V(IV), 17 octahedral for Fe(III), 18 Co(II), 19 and Ni(II),20 and presumably
distorted terahedral for Cu(II).21 All these derivatives present electronic spectra and magnetic moments
characteristic of these metal ions in the above mentioned surroundings. 17"21 In the EPR spectrum of the
Cu(II) complex 16, a large snal was detected with g+/- 1.95 and g//= 2.23, characteristic of Cu(II) in
distorted tetrahedral geometry,z
The diamagnetic complexes 9-11 and 17 had 1H-NMR spectra similar to that of 8, except for the
fact that. the SO NH2 resonance, a broad singlet (2H) at 8.48 ppm in the spectrum of 8, appeared as very
broad sgnals at ].50-8.55 ppm in the spectra of the complexes (data not shown), which were integrated for
H, obviously due to the fact that the sulfonamido moiety was deprotonated.
The above data prompted us to propose tetrahedral geometries for Zn(II), Cd(II) and Hg(II) in the
newly prepared compounds, whereas the silver derivative probably contains Ag(I) in a linear geometry.
Thus, the donor system of the bidentate ligand used for the preparation of metal complexes reported
here is quite similar to those of acetazolamide 1, methazolamide 3 and ethoxzolamide 4,9,1 consisting of the
deprotonated sulfonamide moiety and the endocyclic N-3 atom of the thiadiazolic ring. An exception seems
to be the Ag(I) derivative 17, possessing IR and electronic spectra quite different of the other prepared
complexes, which prompted us to hypothesize that the ligand acts monodentately in this case, by means of
the deprotonated sulfonamido moiety, whereas the second coordination position of Ag(I) is occupied by the
imidazolic nitrogen o,f another ligand molecule, leading thus to a polynuclear derivative as shown
schematically below. In fact, some Ag(I) complexes of aromatic (bactericidal) sulfonamides were shown to
possess such a structure.22 The proposed structures for the new derivatives are Shown below.
N, HN02S
9: M=Zn; 111: M=Cd
11:M = Hg; 16: M = Cu
’N
OH2
N’
S \N ..... HNO2S < S02N N "4""S
N
H20 ’ 14: M = Co; 15: M = Ni
’’N 0
N... \ !
HNO2S N .............
t3
N---N
’1 "--," ,
17’
The presence of the imidazolic nitrogen atom of the ligand in complexes 9-16, which presumably
participates in coordination of the Ag(I) ions in complex 17, but is free in the other compounds, prompted
us to try the preparation of polynuclear complexes involving this particular atom. Thus, treatment of a
solution of the Zn(II) derivative 9 in DMSO with an equimolar amount of CuCI2.2H20 dissolved in the
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same solvent led to a clear greenish-blue solution, from which, by addition of diethyl ether precipitated a
green powder (complex 18) which by analysis led to the following minimal formula: [CuZnL2C12] (found:
Cu, 12.1; Zn, 12.0; C, 17.6; H, 0.8; N, 20.5; C1, 13.0%; CuZnCsH6N804S4C12 requires: Cu, 11.8; Zn,
12.2; C, 17.9; H, 1.1; N, 20.9; CI, 13.2%). The complex is a non-electrolyte, having an IR and solution
electronic spectra highly similar to those of complex 16. Importantly, in the IR spectrum of 15, similarly to
that of the Ag(I) derivative 17, the C=N vibration is splitted: a band at 1610 and another one at 1580 cm" were evidenced (data not shown). These data prompted us to propose the structure below for this polynuclear
complex.
Compounds 8-18 prepared in this work were assayed as inhibitors of two pure CA isozymes (8 has
been tested previously6a against crude red cell murine CA, which is a mixture ofCA I and CA II,z behaving
as a very potent, inhibitor, with. a. KI of 0.65 nM, determined by the method of Philpot and Philpot, which is
a pH-changng method momtonng the hydration of CO2 in the presence of the enzyme and its inhibitors).
Our inhibition data, determined by the method of Poker and Stone,5 for another reaction catalyzed by these
enzyme, i.e., ester hydrolysis, are shown in Table IV.
. \ HNO2 N- N
SO2NH N
/
N\ HN02S Cl
Cu ...... N \ /
18
Table IV: Biological activity data of sulfonamide CA inhibitors and their metal complexes (IC50 the mean
of two different assays represents the molarity of inhibitor producing a 50% decrease of enzyme specific
activity for the p-nitrophenyl acetate hydrolysis reaction)15.
Compound IC50 (l.tM)
CA a CA IIa
1 (acetazolamide) 90 1.10
3 (methazolamide) 120 3.50
8 20.8 0.15
9 10.5 0.09
10 8.4 0.05
11 8.0 0.03
12 14.7 0.10
13 40.2 0.55
14 5.8 0.03
15 7.0 0.05
16 2.5 0.03
17 2.0 0.03
18 1.8 0.02
aHuman (cloned) isozyme;
As seen from data of Table IV, all the prepared complexes act as very effective inhibitors against
both CA isozymes, being in fact much better than the clinically used and potent inhibitors acetazolamide 1
and methazolamide 3 (used as standards). Our inhibition data confirmed previous data ofBamish et al.6a that
compound $ is a very potent inhibitor (although the assay methods and the enzyme preparations in the two
studies are different, which explains in fact the diverse inhibition parameters obtained). As for other metal
complexes of sulfonamide CA inhibitors, previously reported by us,9,1 the newly prepared complexes act
generally as much more potent inhibitors than the parent sulfonamide. In this case the only exception is the
iron derivative 13 which, although being a stronger inhibitor than acetazolamide, is less effective than $,
against both isozymes. One should note the good inhibitory properties of the new complexes against CA
(an isozyme more resistant to inhibition by sulfonamides, as compared to CA II),. which is an exciting
discovery due to the fact that this isozyme is highly abundant in vascular endothelium24
2c 6 24 where it mediates vascular tonus and other physiological processes. The Ag(I) derivative 17 and the
polynuclear compound 18 are particularly active in inhibiting this isozyme.
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In conclusion, this study reports an efficient synthetic method for a strong CA inhibitor, imidazo-
[2,1-b]-l,3,4-thiadiazole-2-sulfonamide, the preparation and characterization of some of its mono- and
polynuclear metal complexes, and their inhibitory effect against two isozymes, CA I and CA II of human
origin. The new complexes are effective inhibitors of both CAs, showing notable inhibition against CA I, an
enzyme involved in vascular processes.
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